REGENXBIO Inc. RGNX
We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects.
Our investigational gene therapies use adeno-associated virus (AAV) vectors from our proprietary gene delivery platform, which we call our NAV® Technology Platform. AAV vectors are non-replicating viral delivery vehicles that are not known to cause disease. Our NAV Technology Platform has consisted of exclusive rights to a large portfolio of AAV vectors (NAV Vectors), including commonly used AAV8 and AAV9. We believe this platform forms a strong foundation for our current clinical-stage programs and, with our ongoing research and development, we expect to continue to expand our platform and pipeline of potential AAV vector-based gene therapies. Our NAV Technology Platform is the foundation for commercial and investigational AAV therapeutics that have treated thousands of patients through our clinical pipeline and NAV licensees.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170.4M | $83.3M | $90.2M | $112.7M | $470.3M | $154.6M | $35.2M | $218.5M | $10.4M | $4.6M |
| Cost of revenue | — | $33.6M | $37.2M | $54.5M | $51.8M | $35.7M | $8.2M | $9.6M | $1.7M | $98.0K |
| Gross profit | — | $49.8M | $53.0M | $58.2M | $418.5M | $118.9M | $27.0M | $208.9M | $8.7M | $4.5M |
| R&D | $228.3M | $208.5M | $232.3M | $242.5M | $181.4M | $166.3M | $124.2M | $83.9M | $57.2M | $45.5M |
| SG&A | $82.9M | $76.6M | $88.5M | $85.3M | $79.3M | $63.8M | $51.8M | $36.9M | $27.2M | $23.6M |
| Total operating expenses | $331.6M | $316.7M | $358.4M | $375.6M | $310.4M | $273.8M | $184.2M | $130.4M | $86.3M | $69.9M |
| Operating income | -$161.2M | -$233.3M | -$268.1M | -$262.9M | $160.0M | -$119.2M | -$149.0M | $88.1M | -$75.9M | -$65.3M |
| Interest expense | $45.0M | $12.7M | $6.9M | $23.3M | $26.3M | $771.0K | — | — | — | — |
| Pre-tax income | -$193.9M | -$227.1M | -$263.6M | -$280.4M | $141.2M | -$106.0M | -$97.5M | $104.1M | -$73.2M | -$63.4M |
| Income tax | $0 | $0 | $152.0K | $84.0K | $13.4M | $5.2M | $2.8M | $4.2M | $0 | $435.0K |
| Net income | -$193.9M | -$227.1M | -$263.5M | -$280.3M | $127.8M | -$111.2M | -$94.7M | $99.9M | -$73.2M | -$63.0M |
| EPS, basic | -3.76 | -4.59 | -6.02 | -6.50 | 3.01 | -2.98 | -2.58 | 2.99 | -2.45 | -2.38 |
| EPS, diluted | -3.76 | -4.59 | -6.02 | -6.50 | 2.91 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 |
| Shares, diluted (wtd. avg.) | 51.6M | 49.5M | 43.7M | 43.2M | 43.9M | 37.3M | 36.7M | 36.6M | 29.9M | 26.4M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $34.5M | $57.5M | $34.5M | $97.0M | $345.2M | $338.4M | $69.5M | $75.6M | $46.7M | $24.8M |
| Short-term investments | $195.6M | $177.2M | $240.7M | $267.7M | $112.2M | $137.3M | $226.7M | $244.2M | $114.1M | $64.7M |
| Receivables | $26.4M | $20.5M | $24.8M | $28.1M | $32.4M | $43.0M | $38.1M | — | — | — |
| Total current assets | $281.3M | $278.0M | $335.0M | $416.0M | $518.8M | $531.2M | $345.0M | $337.9M | $168.0M | $93.4M |
| Property, plant and equipment | $104.9M | $117.6M | $132.1M | $141.7M | $131.5M | $56.5M | $29.0M | $28.7M | $14.0M | $9.3M |
| Total assets | $453.0M | $466.0M | $574.0M | $833.3M | $1.11B | $708.2M | $497.9M | $543.8M | $198.7M | $172.7M |
| Accounts payable | $21.4M | $22.8M | $22.8M | $27.2M | $11.4M | $10.6M | $6.4M | $4.4M | $4.8M | $1.5M |
| Total current liabilities | $118.1M | $103.2M | $130.3M | $130.4M | $130.5M | $81.4M | $33.7M | $22.2M | $14.4M | $9.7M |
| Total liabilities | $350.3M | $206.3M | $262.2M | $317.1M | $349.6M | $330.4M | $47.7M | $35.0M | $15.6M | $11.0M |
| Retained earnings | -$1.13B | -$932.1M | -$705.0M | -$441.6M | -$161.2M | -$289.1M | -$177.8M | -$83.0M | -$187.8M | -$114.6M |
| Total equity | $102.7M | $259.7M | $311.7M | $516.2M | $764.3M | $377.8M | $450.2M | $508.8M | $183.0M | $161.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$124.0M | -$173.1M | -$218.4M | -$207.5M | $218.9M | -$54.1M | -$107.7M | $104.6M | -$58.0M | -$48.6M |
| Stock-based compensation | $34.6M | $38.5M | $40.3M | $40.8M | $38.8M | $31.9M | $26.9M | $16.6M | $10.6M | $7.0M |
| Capital expenditure | $2.4M | $2.4M | $10.0M | $30.7M | $84.2M | $26.9M | $11.7M | $13.3M | $7.2M | $8.1M |
| Investing cash flow | -$15.9M | $103.4M | $190.9M | -$11.9M | -$406.6M | $122.8M | $93.6M | -$279.4M | -$4.8M | $19.4M |
| Financing cash flow | $116.8M | $92.7M | -$35.0M | -$28.8M | $195.2M | $200.2M | $8.4M | $204.4M | $84.6M | $119.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-155058.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | $10.4M | $218.5M | $35.2M | $154.6M | $470.3M | $112.7M | $90.2M | $83.3M | $170.4M |
| Gross profit | $4.5M | $8.7M | $208.9M | $27.0M | $118.9M | $418.5M | $58.2M | $53.0M | $49.8M | — |
| Net income | -$63.0M | -$73.2M | $99.9M | -$94.7M | -$111.2M | $127.8M | -$280.3M | -$263.5M | -$227.1M | -$193.9M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event Item 8.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |